From Reactive to Predictive: Marta Rodríguez Vélez on the Future of Pharma Quality

You have spent more than two decades in the biopharma industry. What key experiences shaped your journey in quality and operational excellence?

Throughout my career, I have had the opportunity to work across several areas of the pharmaceutical industry—from research to quality, regulatory affairs, and manufacturing operations. That cross-functional exposure has been extremely valuable, because it allowed me to understand how every decision ultimately connects to patient safety.

A particularly defining experience has been working in sterile manufacturing environments, where the margin for error is essentially zero. In aseptic production you quickly learn that quality is not a department — it is a system, a culture, and a responsibility shared by everyone involved in the process.

In recent years, leading digitalization and operational excellence initiatives has also shaped my perspective. It has reinforced my belief that the future of quality lies in integrating science, technology, and quality systems to move from reactive compliance toward predictive assurance.

You started your career in research and moved into quality, compliance, and now strategy. What motivated these transitions?

My motivation has always been impact.

Research gave me a strong scientific foundation, but I soon realized that quality functions are where scientific knowledge translates into real-world patient protection. Working in quality and compliance allowed me to contribute directly to ensuring that medicines are consistently safe, effective, and reliable.

More recently, moving into strategic and operational excellence roles has allowed me to work at a different level—helping organizations design systems that prevent problems rather than react to them. That shift from problem resolution to system improvement is something I find particularly meaningful.

At the Pharma & Biotech Quality Summit, digital transformation and smart quality systems are key themes. How do you see these trends shaping the future of pharma manufacturing?

Digital transformation is fundamentally changing how quality systems operate.

Traditionally, quality has been largely reactive — focused on detecting deviations, investigating issues, and documenting compliance. With the increasing availability of structured data, advanced analytics, and AI-enabled tools, we now have the opportunity to evolve toward predictive quality systems.

This means identifying risks earlier, detecting process drift sooner, and enabling more proactive decision-making. However, the real challenge is not technology itself, but integrating digital tools within existing GMP frameworks while maintaining data integrity, transparency, and regulatory trust.

If implemented thoughtfully, digitalization will allow quality teams to shift from being controllers of compliance to enablers of operational excellence.

What key insight are you most looking forward to sharing with fellow industry leaders at the summit?

The key message I want to share is that predictive quality is not a technology project — it is a system transformation.

Artificial intelligence, advanced analytics, and digital tools can significantly enhance quality oversight, but only if they are supported by strong data foundations, robust quality systems, and a culture that embraces continuous improvement.

My presentation will focus on how organizations can move from traditional compliance models toward predictive assurance, while remaining fully aligned with GMP expectations and regulatory frameworks.

Leadership & Culture

In highly regulated industries, how do you balance compliance requirements with operational efficiency?

Compliance and efficiency are often perceived as competing priorities, but in reality they should reinforce each other.

Well-designed processes that are scientifically sound, well documented, and consistently executed tend to be both compliant and efficient. Many inefficiencies actually originate from poorly designed systems, fragmented digital tools, or reactive approaches to problem solving.

The key is applying risk-based thinking, as promoted by ICH Q9 and modern quality frameworks, and designing processes that are both robust and practical for the people operating them.

What leadership qualities are most important for professionals managing quality and operational transformation in pharma today?

Today’s quality leaders must combine technical credibility, strategic thinking, and the ability to lead cultural change.

As digital technologies become more integrated into pharmaceutical manufacturing, quality leaders must be comfortable engaging with data science, automation, and digital systems. At the same time, they must remain strong guardians of patient safety and regulatory compliance.

Perhaps most importantly, they must be able to connect people, processes, and technology, ensuring that transformation initiatives strengthen—not weaken—the quality culture of the organization.

With increasing focus on data integrity and digitalization, how are quality systems evolving in modern pharmaceutical manufacturing?

Quality systems are gradually becoming more data-centric and interconnected.

Traditionally, quality information was distributed across paper records, isolated systems, and manual reviews. Today we are seeing greater integration between manufacturing systems, laboratory systems, and enterprise quality platforms.

This connectivity enables better traceability, faster investigations, and more advanced analytics. It also raises new challenges related to data governance, validation approaches, and the responsible use of AI, which is why frameworks such as CSA, ALCOA+, and emerging regulatory guidance on AI are becoming increasingly relevant.

Having worked in sterile manufacturing and vaccines, what are the biggest quality challenges companies face today in aseptic operations?

Aseptic manufacturing remains one of the most technically demanding areas of pharmaceutical production.

One of the main challenges today is adapting legacy facilities and processes to meet the expectations of the revised EU GMP Annex 1, particularly in areas such as contamination control strategies, barrier technologies, and process monitoring.

Another challenge is integrating new technologies—automation, robotics, advanced monitoring systems—while ensuring that they truly reduce risk rather than introduce new complexity.

Ultimately, maintaining sterility assurance requires a holistic approach, combining facility design, process control, human factors, and a strong contamination control strategy.

Operational excellence programs are becoming central to pharma manufacturing. Where do companies usually struggle when implementing them?

Many organizations focus heavily on tools and methodologies but underestimate the importance of organizational alignment and cultural change.

Operational excellence is not just about implementing Lean or Six Sigma initiatives; it requires connecting improvement activities with the pharmaceutical quality system, regulatory expectations, and strategic priorities.

When operational excellence becomes embedded in the quality culture—supported by data, leadership engagement, and cross-functional collaboration—it can significantly strengthen both performance and compliance.

One word that defines quality excellence

Reliability.

Most critical GMP principle

Patient safety.

Biggest myth about quality teams

That quality exists to stop processes instead of enabling them to work better.

Data integrity or contamination control — which worries you more?

Both are critical, but contamination control directly impacts product sterility, so it remains one of the most sensitive areas.

One skill every future quality leader should develop

Systems thinking.

Your thoughts on the future of pharma manufacturing in one sentence

The future of pharmaceutical manufacturing will be driven by the integration of science, digital technologies, and quality systems to deliver safer medicines more efficiently.